Cargando…

Delivery of therapeutic oligonucleotides with cell penetrating peptides()

Oligonucleotide-based drugs have received considerable attention for their capacity to modulate gene expression very specifically and as a consequence they have found applications in the treatment of many human acquired or genetic diseases. Clinical translation has been often hampered by poor biodis...

Descripción completa

Detalles Bibliográficos
Autores principales: Boisguérin, Prisca, Deshayes, Sébastien, Gait, Michael J., O'Donovan, Liz, Godfrey, Caroline, Betts, Corinne A., Wood, Matthew J.A., Lebleu, Bernard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7102600/
https://www.ncbi.nlm.nih.gov/pubmed/25747758
http://dx.doi.org/10.1016/j.addr.2015.02.008
_version_ 1783511865242943488
author Boisguérin, Prisca
Deshayes, Sébastien
Gait, Michael J.
O'Donovan, Liz
Godfrey, Caroline
Betts, Corinne A.
Wood, Matthew J.A.
Lebleu, Bernard
author_facet Boisguérin, Prisca
Deshayes, Sébastien
Gait, Michael J.
O'Donovan, Liz
Godfrey, Caroline
Betts, Corinne A.
Wood, Matthew J.A.
Lebleu, Bernard
author_sort Boisguérin, Prisca
collection PubMed
description Oligonucleotide-based drugs have received considerable attention for their capacity to modulate gene expression very specifically and as a consequence they have found applications in the treatment of many human acquired or genetic diseases. Clinical translation has been often hampered by poor biodistribution, however. Cell-penetrating peptides (CPPs) appear as a possibility to increase the cellular delivery of non-permeant biomolecules such as nucleic acids. This review focuses on CPP-delivery of several classes of oligonucleotides (ONs), namely antisense oligonucleotides, splice switching oligonucleotides (SSOs) and siRNAs. Two main strategies have been used to transport ONs with CPPs: covalent conjugation (which is more appropriate for charge-neutral ON analogues) and non-covalent complexation (which has been used for siRNA delivery essentially). Chemical synthesis, mechanisms of cellular internalization and various applications will be reviewed. A comprehensive coverage of the enormous amount of published data was not possible. Instead, emphasis has been put on strategies that have proven to be effective in animal models of important human diseases and on examples taken from the authors' own expertise.
format Online
Article
Text
id pubmed-7102600
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-71026002020-03-31 Delivery of therapeutic oligonucleotides with cell penetrating peptides() Boisguérin, Prisca Deshayes, Sébastien Gait, Michael J. O'Donovan, Liz Godfrey, Caroline Betts, Corinne A. Wood, Matthew J.A. Lebleu, Bernard Adv Drug Deliv Rev Article Oligonucleotide-based drugs have received considerable attention for their capacity to modulate gene expression very specifically and as a consequence they have found applications in the treatment of many human acquired or genetic diseases. Clinical translation has been often hampered by poor biodistribution, however. Cell-penetrating peptides (CPPs) appear as a possibility to increase the cellular delivery of non-permeant biomolecules such as nucleic acids. This review focuses on CPP-delivery of several classes of oligonucleotides (ONs), namely antisense oligonucleotides, splice switching oligonucleotides (SSOs) and siRNAs. Two main strategies have been used to transport ONs with CPPs: covalent conjugation (which is more appropriate for charge-neutral ON analogues) and non-covalent complexation (which has been used for siRNA delivery essentially). Chemical synthesis, mechanisms of cellular internalization and various applications will be reviewed. A comprehensive coverage of the enormous amount of published data was not possible. Instead, emphasis has been put on strategies that have proven to be effective in animal models of important human diseases and on examples taken from the authors' own expertise. Elsevier B.V. 2015-06-29 2015-03-04 /pmc/articles/PMC7102600/ /pubmed/25747758 http://dx.doi.org/10.1016/j.addr.2015.02.008 Text en Copyright © 2015 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Boisguérin, Prisca
Deshayes, Sébastien
Gait, Michael J.
O'Donovan, Liz
Godfrey, Caroline
Betts, Corinne A.
Wood, Matthew J.A.
Lebleu, Bernard
Delivery of therapeutic oligonucleotides with cell penetrating peptides()
title Delivery of therapeutic oligonucleotides with cell penetrating peptides()
title_full Delivery of therapeutic oligonucleotides with cell penetrating peptides()
title_fullStr Delivery of therapeutic oligonucleotides with cell penetrating peptides()
title_full_unstemmed Delivery of therapeutic oligonucleotides with cell penetrating peptides()
title_short Delivery of therapeutic oligonucleotides with cell penetrating peptides()
title_sort delivery of therapeutic oligonucleotides with cell penetrating peptides()
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7102600/
https://www.ncbi.nlm.nih.gov/pubmed/25747758
http://dx.doi.org/10.1016/j.addr.2015.02.008
work_keys_str_mv AT boisguerinprisca deliveryoftherapeuticoligonucleotideswithcellpenetratingpeptides
AT deshayessebastien deliveryoftherapeuticoligonucleotideswithcellpenetratingpeptides
AT gaitmichaelj deliveryoftherapeuticoligonucleotideswithcellpenetratingpeptides
AT odonovanliz deliveryoftherapeuticoligonucleotideswithcellpenetratingpeptides
AT godfreycaroline deliveryoftherapeuticoligonucleotideswithcellpenetratingpeptides
AT bettscorinnea deliveryoftherapeuticoligonucleotideswithcellpenetratingpeptides
AT woodmatthewja deliveryoftherapeuticoligonucleotideswithcellpenetratingpeptides
AT lebleubernard deliveryoftherapeuticoligonucleotideswithcellpenetratingpeptides